Pulmonology

Gynecologic Oncology

Questions discussed in this category

What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?

For example, prolonging life-sustaining measures as they "wait for a miracle" of an unrealistic outcome.

1 Answer available

Would you give checkpoint inhibitor therapy to a cancer patient with known dermatomyositis given the association of checkpoint inhibitor associated myocarditis, myasthenia gravis, and myositis?

6 Answers available

Are there known biomarkers predictive of IRAEs?

3 Answers available

When can abdominal surgery be safely performed for presumptive ovarian cancer in a patient with recent pulmonary emboli?

(Normal oxygenation and echo)

1 Answer available

How do you manage steroid-refractory immune checkpoint inhibitor induced pneumonitis?

4 Answers available

What is your preferred steroid sparing therapy in a patient experiencing a severe checkpoint inhibitor toxicity and not responding to high dose IV steroids?

2 Answers available

Papers discussed in this category

Journal for immunotherapy of cancer, 2017-11-21

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

J Immunother Cancer, 2021 Feb

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.

J Natl Compr Canc Netw,

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

Ann Oncol,

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

J Immunother Cancer,

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.

J Immunother Cancer,

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis.

J Clin Oncol, 2021 Dec 20

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

J Natl Compr Canc Netw,

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.

Future Sci OA, 2020 Aug 03

A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy.

Cancer Treat Res Commun, 2022 Jul 01

Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy.

Trends Immunol, 2021 Mar 10

Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines.

Related Topics in Pulmonology